Fertility and Sterility
Volume 91, Issue 4, Supplement , Pages 1378-1380, April 2009

GnRH agonist versus GnRH antagonist in controlled ovarian hyperstimulation: their role in patients with an unfavorable prognosis a priori

  • Raoul Orvieto, M.D., M.M.Sc.

      Affiliations

    • Department of Obstetrics and Gynecology, Barzilai Medical Center, Ashkelon, Israel
    • BenGurion University School of Medicine, Beer Sheva, Israel
    • Corresponding Author InformationReprint requests: Professor Raoul Orvieto M.D., M.M.Sc., Director, Infertility and IVF Unit, Department of Obstetrics and Gynecology, Barzilai Medical Center, Ashkelon 78278, Israel (FAX: 972-8-6745134).
    • ,
  • Roy Homburg, F.R.C.O.G.

      Affiliations

    • Department of Obstetrics and Gynecology, Barzilai Medical Center, Ashkelon, Israel
    • ,
  • Simion Meltcer, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Barzilai Medical Center, Ashkelon, Israel
    • ,
  • Jacob Rabinson, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Barzilai Medical Center, Ashkelon, Israel
    • ,
  • Eyal Y. Anteby, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Barzilai Medical Center, Ashkelon, Israel
    • BenGurion University School of Medicine, Beer Sheva, Israel
    • ,
  • Shimon Scharf, M.D., M.P.H.

      Affiliations

    • Department of Obstetrics and Gynecology, Barzilai Medical Center, Ashkelon, Israel
    • BenGurion University School of Medicine, Beer Sheva, Israel

Received 8 February 2008; received in revised form 12 April 2008; accepted 12 April 2008. published online 04 August 2008.

In an attempt to examine the influence of the type of GnRH analogue used during controlled ovarian hyperstimulation on IVF outcome in patients with an unfavorable outcome a priori, we studied 728 consecutive cycles in patients with repeated IVF failure. In patients with repeated failure, the GnRH agonist group showed significantly higher clinical pregnancy rate compared with the GnRH antagonist group (20.8% vs 14.5%).

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 R.O. has nothing to disclose. R.H. has nothing to disclose. S.M. has nothing to disclose. J.R. has nothing to disclose. E.A. has nothing to disclose. S.S. has nothing to disclose.

PII: S0015-0282(08)00898-4

doi:10.1016/j.fertnstert.2008.04.028

Fertility and Sterility
Volume 91, Issue 4, Supplement , Pages 1378-1380, April 2009

Article Tools